Teutonic launches Celecoxibe, generic unheard of in the pharmaceutical market

The German Laboratory/Pfizer presents, this week, the Celecoxibe, the first generic of this active ingredient in Brazil, used in the symptomatic treatment of osteoarthritis and rheumatoid arthritis (chronic inflammation in the joints). The product comes in four presentations: of 200 milligrams, with 30, 15 and 10, and 100 mg capsules with 20 capsules.
The medicine is about 35% more economical compared with the reference product. Thiago Wolf Matos, pharmacist in the release notes that the Celecoxibe also acts on the relief of symptoms of inflammatory diseases in the joints of the spine, hips and shoulders and acute postoperative pain of Orthopedic surgeries and dental. "The launch is indicated for the relief of menstrual cramps and back pain (lumbago)."
The launch of Celecoxibe, Pfizer Celebrates generic is another fruit of the partnership between Teutonic and Pfizer, resulting in a most cost-effective therapeutic option for patients using the medication.
The drug, which is sold only under medical prescription with revenue retention, is contraindicated for patients with hypersensitivity to celecoxibe, any other component of the formula and the sulfonamides such as sulfadizina and sulfamethoxazole. The product should also not for use by individuals who have made asthma, urticaria, allergic reaction after using aspirin or other non-steroidal anti-inflammatory, liver disease and severe renal insufficiency.